Bringing possibility to Duchenne.

Meet Liam, age 19, deletion of exons 48-50

Meet Graysen, age 2, deletion of exons 48-50

Meet Ryan, age 11, deletion of exons 48-50

EXONDYS 51 is the first FDA-approved Duchenne muscular dystrophy treatment for patients who have a confirmed genetic mutation in the dystrophin gene that can be treated by skipping exon 51. In some patients, it helps the body make a shorter form of the dystrophin protein.

Approved under accelerated approval.
Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

Discover EXONDYS 51

Who can take it?

Learn the importance of understanding your genetic mutation and what it means to be amenable to treatment with EXONDYS 51.

Learn About Amenability

Starting Treatment

Starting treatment with EXONDYS 51? Let us take you through the process so you know what to expect.

Explore the Process

Getting Support

With the SareptAssist patient support program, we'll help you navigate the process of starting therapy with EXONDYS 51.

How We Can Help

"My son, Zyler, has Duchenne. Any mother with a son with Duchenne wants to do anything they can to get access to medication. SareptAssist guided us every step of the way."

Holly, Zyler's mom

Zyler, age 6, deletion of exons 48-50 and his family

Ongoing support and information from Sarepta.

Receive future tips and support about treatment with EXONDYS 51.

Stay informed on SareptAssist services.

Find out about patient resources that are available.

Get updates about news and research on Duchenne from Sarepta.

WHAT IS EXONDYS 51 (eteplirsen)?

EXONDYS 51 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 51.

EXONDYS 51 was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions: Allergic reactions, including wheezing, chest pain, cough, rapid heart rate, and hives have occurred in patients who were treated with EXONDYS 51. Seek immediate medical care if signs and symptoms of allergic reactions occur.

Adverse Reactions: Side effects that have occurred at least 25% more often in patients treated with EXONDYS 51 than in patients treated with an inactive intravenous (IV) infusion were problems with balance (38%, 0%), vomiting (38%, 0%), and skin irritation (25%, 0%). The most common side effects were problems with balance and vomiting.

The most common side effects that occurred in greater than 10% of patients receiving EXONDYS 51 in other clinical trials were headache, cough, rash, and vomiting.

What do I do if I have side effects?

Ask your healthcare provider for advice about any side effects that concern you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

The information provided here does not include all that is known about EXONDYS 51. To learn more, talk with your healthcare provider.

Before receiving this infusion, please see the full Prescribing Information for EXONDYS 51 (eteplirsen).